High materiality8/10
Neurocrine price target raised to $222 from $200 at Guggenheim
Why it may matterVerify against the original reporting
buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
NBIX received an analyst target update from Guggenheim.
- Guggenheim raises NBIX target to $222 from $200.
Key facts
- 01
Target: $222
- 02
Posted price: $185.5
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.